Neurocrine Biosciences, Inc. is a leading neuroscience-focused, biopharmaceutical company headquartered in San Diego, CA, with a single purpose: to relieve suffering for people with great needs but few options. Neurocrine Biosciences was founded in 1992 and has grown today to 1,436 U.S.-based employees who are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.
Innovation
Neurocrine Biosciences was founded by scientists driven to discover potential treatments for rare and under-addressed diseases. For three decades, Neurocrine has applied unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis (in collaboration with AbbVie), and uterine fibroids (in collaboration with AbbVie), as well as a robust pipeline including multiple compounds in mid- to latephase clinical development across core therapeutic areas.
Talent Development
Neurocrine Biosciences is proud to be recognized by Great Place to Work® and FORTUNE as one of the 2024 Best Workplaces in Biopharma™, ranking No. 7. With a 90th percentile ranking in employee engagement favorability among biopharmaceutical companies, the company demonstrates its strong commitment to fostering a positive work environment. In 2023, Neurocrine invested over $575,000 in employee training and development, with 72% of employees participating in professional and leadership training, a significant rise from 40% in 2022. Dedicated to advancing diversity, equity, and inclusion (DE&I), Neurocrine’s comprehensive DE&I program offers mentorships and internships for diverse employees and students. The company proudly supports the Wylie Vale Neurocrine Biosciences SD2 Scholarship, aimed at helping underrepresented students pursue STEM degrees. Neurocrine also actively engages in building a strong STEM talent pipeline by participating in site visits and career fairs at Historically Black Colleges and Universities (HBCUs). Their partnerships with organizations like the Ocean Discovery Institute and San Diego Squared further underscore their commitment to empowering underrepresented students to succeed in STEM fields and contribute to the scientific community.
Social Responsibility
In 2024, Neurocrine Biosciences moved into a new, environmentally sustainable campus in San Diego, designed to meet LEED Silver standards. Neurocrine is committed to recycling over 98% of its hazardous waste using EPA-aligned methods such as solvent reclamation and fuel blending, partnering with a global leader to drive recycling efforts toward 100%. Neurocrine’s 2nd Generation manufacturing process for INGREZZA (valbenazine) capsules has reduced waste by 53%, water use by 32%, and cycle-time by 43%, all while increasing product yield, demonstrating their dedication to sustainability across profit, people, and the planet.
FINALISTS:
Ardelyx, Inc.
BeiGene
Exelixis
ImmunoGen
Neurocrine Biosciences, Inc.
